<DOC>
	<DOCNO>NCT00317772</DOCNO>
	<brief_summary>The purpose study : 1 . To determine dose limit toxicity ( DLT ) maximum tolerate dose ( MTD ) weekly topotecan combination standard dose gefitinib patient relapse , platinum-resistant , ovarian , peritoneal fallopian tube cancer epidermal growth factor receptor ( EGF-R ) positive ( &gt; /= 1+ ) . 2 . To determine response rate response duration patient population treat maximum tolerate dose ( MTD ) topotecan administer weekly schedule combination standard dose gefitinib , give way mouth ( PO ) daily .</brief_summary>
	<brief_title>Topotecan Gefitinib ( Iressa ) Ovarian , Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description>Gefitinib inhibit activity molecule present cancer cell play role cancer cell growth . Topotecan FDA approve drug use treat ovarian cancer still present treatment chemotherapy . It also use treat recurrent ovarian cancer ( patient whose cancer return cancer-free period time ) . Before treatment start , complete physical exam , routine blood test ( 2-3 teaspoon ) , chest x-ray , CT scan MRI . Women able child must negative blood pregnancy test . There 2 phase study . In first phase , 3 different dose level topotecan study . The dose topotecan receive depend enrol . It also depend whether participant side effect treatment . Although dose topotecan vary , dose gefitinib participant . Up 6 participant may treat dose . The goal portion study find high safe dose drug combination . Up 18 patient treated part study . Once high safe dose topotecan found , second phase study begin . In phase , participant receive dose topotecan gefitinib . Up 40 patient enrolled part study ( 6 1st portion study . Each treatment cycle 28 day long . You take one gefitinib tablet mouth every day begin Day 1 . In addition , give topotecan catheter ( tube ) place vein 30 minute Days 1 , 8 , 15 . Blood test check kidney , liver , bone marrow function complete checkup ( physical examination , include pelvic rectal exam ) do course therapy month treatment end . About 2-3 teaspoon blood collect routine blood test time blood drawn study . Follow CT scan MRI scan do every 2 3 cycle evaluate response treatment . You take study disease get bad intolerable side effect occur . If complete response therapy ( evidence cancer ) treatment continue additional 6 month stop . All treatment give outpatient basis UTMDACC . You monitor least 30 day last dose therapy . If side effect relate treatment combination , monitor long ( side effect go away ) . This investigational study . Both gefitinib topotecan FDA approve commercially available . However , use together study investigational . A total 52 patient take part study . All enrol UTMDACC .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Women platinumresistant , histologically confirm epithelial ovarian , fallopian tube peritoneal cancer . Resistance define : Progression disease platinum chemotherapy , progression disease within 6 month complete platinum chemotherapy , failure achieve complete response , persistent macroscopic disease , adequate trial primary therapy . EGFR expression must positive ( e.g. , 1+ great ) See appendix G. Patients known hypersensitivity platinum compound , fail desensitization regimen , opinion investigator , good candidate desensitization , eligible . Patients must measurable disease . Unlimited number prior chemotherapy regimen allow . Zubrod performance status &lt; /= 2 . Patients must adequate hepatic , renal , bone marrow function , define serum creatinine &lt; /= 2 mg/dl ( estimate creatinine clearance 50 ml/min ) ; total bilirubin &lt; /=2.0 X upper limit normal ( ULN ) ; alanine aminotransferase ( ALT ) &lt; /= 2X ULN ; white blood count ( WBC ) &gt; /= 3,000/mm3 ; absolute neutrophil count ( ANC ) &gt; /= 1,500/mm3 ; platelet &gt; /= 100,000/mm3 . At least three week must elapse completion chemotherapy radiation therapy . At least 30 day must elapse completion treatment nonapproved investigational drug . Patients must sign informed consent indicate aware investigational nature study , keep policy hospital . The approved consent append protocol . Women childbearing potential must willing practice acceptable method birth control prevent pregnancy . Patients borderline low malignant potential tumor eligible . Patients prior therapy topoisomerase I inhibitor . Patients pregnant lactate . Concurrent chemotherapy , radiation therapy , surgery ( exclude palliative radiation ) . Concurrent , uncontrolled , medical psychiatric disorder . Patients active infection . Patients know hypersensitivity topotecan iressa . Patients severe cardiovascular disease ( i.e . arrhythmias require chronic treatment congestive heart failure ) ( NYHA classification III IV ) . History malignancy ( except nonmelanoma skin cancer carcinoma situ cervix ) , unless complete remission therapy disease minimum 5 year . Patients overt psychosis mental disability otherwise incompetent give inform consent . Patients prior antiEGFR therapy ( i.e . Tarceva , Cetuximab ) . Evidence significant clinical disorder laboratory find make undesirable subject participate trial . Concomitant use phenytoin , carbamazepine , rifampicin , barbiturate , St. John 's Wort . Any evidence clinically active interstitial lung disease ( patient chronic stable radiographic change asymptomatic eligible ) .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Epithelial Ovarian Cancer</keyword>
	<keyword>Peritoneal Cancer</keyword>
	<keyword>Fallopian Tube Cancer</keyword>
	<keyword>Epidermal Growth Factor</keyword>
	<keyword>Platinum Hypersensitivity</keyword>
	<keyword>Hycamtin</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>Iressa</keyword>
	<keyword>Topotecan</keyword>
	<keyword>EGFR</keyword>
</DOC>